Unknown

Dataset Information

0

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.

ABSTRACT: BACKGROUND:High frequency of MNNG HOS transforming (MET) exon 14 skipping mutation (MET exon 14?) has been reported in pulmonary sarcomatoid carcinomas (PSCs). However, the frequencies differ greatly. Our study aims to investigate the frequency of MET alterations and the correlations among MET exon 14?, amplification, and protein overexpression in a large cohort of PSCs. MET exon 14?, amplification, and protein overexpression were detected in 124 surgically resected PSCs by using Sanger sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC) respectively. MET exon 14? was identified in 9 (7.3%) of 124 cases, including 6 pleomorphic carcinomas, 2 spindle cell carcinomas and 1 carcinosarcoma. MET amplification and protein overexpression were detected in 6 PSCs (4.8%) and 25 PSCs (20.2%), respectively. MET amplification was significantly associated with overexpression (P?

SUBMITTER: Liu XW 

PROVIDER: S-EPMC7492996 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.

Liu Xue-Wen XW   Chen Xin-Ru XR   Rong Yu-Ming YM   Lyu Ning N   Xu Chun-Wei CW   Wang Fang F   Sun Wen-Yong WY   Fang San-Gao SG   Yuan Jing-Ping JP   Wang Hui-Juan HJ   Wang Wen-Xian WX   Huang Wen-Bin WB   Xu Jian-Ping JP   Yue Zhen-Ying ZY   Chen Li-Kun LK  

Translational oncology 20200910 12

<h4>Background</h4>High frequency of MNNG HOS transforming (MET) exon 14 skipping mutation (MET exon 14Δ) has been reported in pulmonary sarcomatoid carcinomas (PSCs). However, the frequencies differ greatly. Our study aims to investigate the frequency of MET alterations and the correlations among MET exon 14Δ, amplification, and protein overexpression in a large cohort of PSCs. MET exon 14Δ, amplification, and protein overexpression were detected in 124 surgically resected PSCs by using Sanger  ...[more]

Similar Datasets

Unknown Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification.
| S-EPMC10318750 | biostudies-literature
Unknown Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring <i>MET</i> exon 14 skipping mutation: a case report.
| S-EPMC6735656 | biostudies-literature
Unknown MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
| S-EPMC8649016 | biostudies-literature
Unknown MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
| S-EPMC6675391 | biostudies-literature
Unknown Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
| S-EPMC8264054 | biostudies-literature
Unknown MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
| S-EPMC4911276 | biostudies-literature
Unknown MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
| S-EPMC4828128 | biostudies-literature
Unknown [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
| S-EPMC6058657 | biostudies-literature
Unknown The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
| S-EPMC8524022 | biostudies-literature
Unknown Lung Cancer with <i>MET</i> exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
| S-EPMC8290191 | biostudies-literature